Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 14/20 | 0.93 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.93 |
| ▸ | MEN1 | O00255 | 1/20 | 0.93 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.93 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.93 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.93 |
| ▸ | CCR2 | P41597 | 1/20 | 0.93 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 1/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.93 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.93 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5611617 | 0.96 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| SCHEMBL29490414 | 0.96 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL19038 | 0.96 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7473839 | 0.95 | CXCR4 (0.93) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7471461 | 0.95 | CXCR4 (0.93) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7474513 | 0.95 | CXCR4 (0.93) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL414153 | 0.95 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7610931 | 0.95 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7612104 | 0.95 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL6889125 | 0.95 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127198-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TOXIC GAS EXPOSURE | THE UAB RESEARCH FOUNDATION | 2023-04-27 | — | — | US | disclosed |
| US-9827224-B2 | Methods and compositions for ameliorating pancreatic cancer | UNIVERSITY OF SOUTH ALABAMA (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160220532-A1 | METHODS AND COMPOSITIONS FOR AMELIORATING PANCREATIC CANCER | UNIVERSITY OF SOUTH ALABAMA | 2016-08-04 | — | — | US | disclosed |
| US-20160081980-A1 | Composition Comprising AMD3100 For Preventing or Treating Bone Diseases | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY - ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-24 | — | — | US | disclosed |
| US-9267934-B2 | Methods and compositions for ameliorating pancreatic cancer | UNIVERSITY OF SOUTH ALABAMA (US) | 2016-02-23 | — | — | US | disclosed |
| US-20130281423-A1 | METHODS AND COMPOSITIONS FOR AMELIORATING PANCREATIC CANCER | UNIVERSITY OF SOUTH ALABAMA (US) | 2013-10-24 | — | — | US | disclosed |
| US-20080214509-A1 | Methods for enhancing the efficacy of vascular disrupting agents | OXIGENE, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220532-A1 | METHODS AND COMPOSITIONS FOR AMELIORATING PANCREATIC CANCER | CXCL12, CXCR4, CXCR3 | CXCR4 2/4885HRH3 1214/4885MEN1 3059/4885 |
| US-20080214509-A1 | Methods for enhancing the efficacy of vascular disrupting agents | CXCL12, CXCR4, CXCR2 | CXCR4 2/4885HRH3 2418/4885MEN1 2440/4885 |
| US-20230127198-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TOXIC GAS EXPOSURE | AREG, CCL11, BDKRB2 | CXCR4 391/4885HRH3 301/4885MEN1 1555/4885 |
| US-20160081980-A1 | Composition Comprising AMD3100 For Preventing or Treating Bone Diseases | CXCL12, CCL11, SDF4 | CXCR4 4/4885HRH3 1136/4885MEN1 2802/4885 |
| US-20130281423-A1 | METHODS AND COMPOSITIONS FOR AMELIORATING PANCREATIC CANCER | CXCL12, CXCR4, CXCR3 | CXCR4 2/4885HRH3 1214/4885MEN1 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.